Voyager Therapeutics and AbbVie announce collaboration to develop vectorized antibodies
Voyager Therapeutics and AbbVie announced an exclusive, global strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for potential treatment of Parkinson’s and other diseases. February 22, 2019